Search Results - C. N. Harrison

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS by J.-J. Kiladjian, A. Tefferi, F. Passamonti, A. Vannucchi, M. Talpaz, F. Cervantes, C. N. Harrison, R. A. Mesa, J. Mascarenhas, N. Schaap, S. Verstovsek, T. Devos, S. Rose, J. Zhang, O. Sy, A. Pardanani

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  2. 2

    P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO... by J. Mascarenhas, C. N. Harrison, J.-J. Kiladjian, R. S. Komrokji, S. Koschmieder, A. M. Vannucchi, T. Berry, D. Redding, L. Sherman, S. Dougherty, L. Peng, L. Sun, F. Huang, Y. Wan, F. M. Feller, A. Rizo, S. Verstovsek

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  3. 3

    P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREAT... by V. Gupta, A. Yacoub, S. Verstovsek, R. A. Mesa, C. N. Harrison, G. Barosi, J.-J. Kiladjian, H. J. Deeg, S. Fazal, L. Foltz, R. J. Mattison, C. B. Miller, V. Parameswaran, C. Hernandez, J. Zhang, M. Talpaz

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  4. 4

    C046 | PREDICTIVE VALUE OF MICROBIOME AND METABOLOMIC BIOMARKERS IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA by A. Campagna, F. Clasen, T. Portlock, M. Zampini, F. Ficara, L. Crisafulli, M. Brindisi, G. Martano, E. Saba, M. Ubezio, A. Russo, G. Todisco, G. Maggioni, L. Lanino, A. Buizza, N. Pinocchio, D. Ventura, F. Viviani, E. Torre, R. Antunes Dos Reis, E. Rocchi, G. Castellani, M. Uhlen, C.N. Harrison, S. Kordasti, M.G. Della Porta, S. Shoaie

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  5. 5

    P1033: A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET) by F. Palandri, D. M. Ross, T. Cochrane, C. Tate, S. W. Lane, S. R. Larsen, A. T. Gerds, A. B. Halpern, J. Shortt, J. M. Rossetti, K. M. Pettit, J. Liang, A. Mead, M. Marchetti, A. Vannucchi, A. Wilson, J. R. Göthert, M. Hanna, A. Jones, J. Peppe, G. Natsoulis, T. McClure, W.-J. Hong, W. S. Stevenson, C. N. Harrison, M. Talpaz, N. Vianelli, H. Y. Rienhoff, Jr.

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: